{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:52:20Z","timestamp":1791107540462,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The National Natural Science Foundation of China","award":["82573102"],"award-info":[{"award-number":["82573102"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The National Natural Science Foundation of China","award":["82173038"],"award-info":[{"award-number":["82173038"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The National Natural Science Foundation of China","award":["82273428"],"award-info":[{"award-number":["82273428"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501700"],"award-info":[{"award-number":["2023ZD0501700"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501703"],"award-info":[{"award-number":["2023ZD0501703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04583-3","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:26:54Z","timestamp":1791044814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib"],"prefix":"10.1007","author":[{"given":"Jiahui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-7525","authenticated-orcid":false,"given":"Dongsheng","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"4583_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.602726","volume":"27","author":"L Mao","year":"2021","unstructured":"Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D, et al. Mutation spectrum of EGFR from 21,324 Chinese patients with non-small cell lung cancer (NSCLC) successfully tested by multiple methods in a CAP-accredited laboratory. Pathol Oncol Res. 2021;27:602726. https:\/\/doi.org\/10.3389\/pore.2021.602726.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4583_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40364-024-00686-7","volume":"12","author":"J Feng","year":"2024","unstructured":"Feng J, Zhang P, Wang D, Li Y, Tan J. New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology. Biomark Res. 2024;12(1):136. https:\/\/doi.org\/10.1186\/s40364-024-00686-7.","journal-title":"Biomark Res"},{"key":"4583_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.593852","volume":"10","author":"S Z\u00f6chbauer-M\u00fcller","year":"2020","unstructured":"Z\u00f6chbauer-M\u00fcller S, Kaserer B, Prosch H, Cseh A, Solca F, Bauer MJ, et al. Case report: afatinib treatment in a patient with NSCLC harboring a rare EGFR exon 20 mutation. Front Oncol. 2020;10:593852. https:\/\/doi.org\/10.3389\/fonc.2020.593852.","journal-title":"Front Oncol"},{"issue":"10","key":"4583_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"2","key":"4583_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s1470-2045(09)70364-x","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138. https:\/\/doi.org\/10.1016\/s1470-2045(09)70364-x.","journal-title":"Lancet Oncol"},{"issue":"22","key":"4583_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"},{"issue":"2","key":"4583_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","volume":"8","author":"GR Oxnard","year":"2013","unstructured":"Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179\u201384. https:\/\/doi.org\/10.1097\/JTO.0b013e3182779d18.","journal-title":"J Thorac Oncol"},{"key":"4583_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2018.10.007","volume":"125","author":"AF Cardona","year":"2018","unstructured":"Cardona AF, Rojas L, Zatarain-Barr\u00f3n ZL, Freitas HC, Granados ST, Castillo O, et al. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer. 2018;125:265\u201372. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.007.","journal-title":"Lung Cancer"},{"issue":"1","key":"4583_CR9","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/s1470-2045(11)70129-2","volume":"13","author":"H Yasuda","year":"2012","unstructured":"Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23-31. https:\/\/doi.org\/10.1016\/s1470-2045(11)70129-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4583_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","volume":"25","author":"M Beau-Faller","year":"2014","unstructured":"Beau-Faller M, Prim N, Ruppert AM, Nanni-Met\u00e9llus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdt418.","journal-title":"Ann Oncol"},{"issue":"18","key":"4583_CR11","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1002\/cncr.29493","volume":"121","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121(18):3212\u201320. https:\/\/doi.org\/10.1002\/cncr.29493.","journal-title":"Cancer"},{"issue":"12","key":"4583_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/bjc.2016.372","volume":"115","author":"JL Kuiper","year":"2016","unstructured":"Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Gr\u00fcnberg K, Bloemena E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 2016;115(12):1504\u201312. https:\/\/doi.org\/10.1038\/bjc.2016.372.","journal-title":"Br J Cancer"},{"key":"4583_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","volume":"114","author":"HY Tu","year":"2017","unstructured":"Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;114:96\u2013102. https:\/\/doi.org\/10.1016\/j.lungcan.2017.11.005.","journal-title":"Lung Cancer"},{"issue":"2","key":"4583_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4143\/crt.2018.151","volume":"51","author":"S Byeon","year":"2019","unstructured":"Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, et al. Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea. Cancer Res Treat. 2019;51(2):623\u201331. https:\/\/doi.org\/10.4143\/crt.2018.151.","journal-title":"Cancer Res Treat"},{"issue":"10","key":"4583_CR15","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.019.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4583_CR16","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/j.cllc.2018.02.007","volume":"19","author":"J Yuan","year":"2018","unstructured":"Yuan J, Li B, Zhang N, Zhu H, Zhou L, Zhang L, et al. Clinical implications of the BIM deletion polymorphism in advanced lung adenocarcinoma treated with gefitinib. Clin Lung Cancer. 2018;19(4):e431\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2018.02.007.","journal-title":"Clin Lung Cancer"},{"key":"4583_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399975","volume":"15","author":"M Hu","year":"2024","unstructured":"Hu M, Zhong C, Wang J, Chen J, Zhou T. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Front Immunol. 2024;15:1399975. https:\/\/doi.org\/10.3389\/fimmu.2024.1399975.","journal-title":"Front Immunol"},{"issue":"1","key":"4583_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07114-w","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang K, Ge Y, Xu Y, Zhang C, Wang L. Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer. J Transl Med. 2025;23(1):1178. https:\/\/doi.org\/10.1186\/s12967-025-07114-w.","journal-title":"J Transl Med"},{"issue":"21","key":"4583_CR19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1200\/jco-25-00763","volume":"43","author":"Z Piotrowska","year":"2025","unstructured":"Piotrowska Z, Passaro A, Nguyen D, Ruiter G, Soo RA, Ho-Fun Lee V, et al. Zipalertinib in patients with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer previously treated with platinum-based chemotherapy with or without amivantamab. J Clin Oncol. 2025;43(21):2387\u201397. https:\/\/doi.org\/10.1200\/jco-25-00763.","journal-title":"J Clin Oncol"},{"key":"4583_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","volume":"145","author":"G Yang","year":"2020","unstructured":"Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186\u201394. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.014.","journal-title":"Lung Cancer"},{"issue":"3","key":"4583_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s2213-2600(23)00379-x","volume":"12","author":"M Wang","year":"2024","unstructured":"Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024;12(3):217\u201324. https:\/\/doi.org\/10.1016\/s2213-2600(23)00379-x.","journal-title":"Lancet Respir Med"},{"issue":"29","key":"4583_CR22","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/jco-25-00788","volume":"43","author":"JC Yang","year":"2025","unstructured":"Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, et al. Phase II dose-randomized study of sunvozertinib in platinum-pretreated non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (WU-KONG1B). J Clin Oncol. 2025;43(29):3198\u2013208. https:\/\/doi.org\/10.1200\/jco-25-00788.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4583_CR23","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/1878-0261.12710","volume":"14","author":"Y Qin","year":"2020","unstructured":"Qin Y, Jian H, Tong X, Wu X, Wang F, Shao YW, et al. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020;14(8):1695\u2013704. https:\/\/doi.org\/10.1002\/1878-0261.12710.","journal-title":"Mol Oncol"},{"issue":"2","key":"4583_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/1878-0261.13327","volume":"17","author":"S Viteri","year":"2023","unstructured":"Viteri S, Minchom A, Bazhenova L, Ou SI, Bauml JM, Shell SA, et al. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol Oncol. 2023;17(2):230\u20137. https:\/\/doi.org\/10.1002\/1878-0261.13327.","journal-title":"Mol Oncol"},{"key":"4583_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.949304","volume":"12","author":"C Shi","year":"2022","unstructured":"Shi C, Xing R, Li M, Feng J, Sun R, Wei B, et al. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations. Front Oncol. 2022;12:949304. https:\/\/doi.org\/10.3389\/fonc.2022.949304.","journal-title":"Front Oncol"},{"issue":"216","key":"4583_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007205","volume":"5","author":"H Yasuda","year":"2013","unstructured":"Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177. https:\/\/doi.org\/10.1126\/scitranslmed.3007205.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4583_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","volume":"19","author":"P Stockhammer","year":"2024","unstructured":"Stockhammer P, Grant M, Wurtz A, Foggetti G, Exp\u00f3sito F, Gu J, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol. 2024;19(2):240\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.001.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4583_CR28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.21037\/tlcr-20-382","volume":"9","author":"CW Xu","year":"2020","unstructured":"Xu CW, Wang WX, Wang D, Wang QM, Pu XX, Zhu YC, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9(5):1853\u201361. https:\/\/doi.org\/10.21037\/tlcr-20-382.","journal-title":"Transl Lung Cancer Res"},{"issue":"30","key":"4583_CR29","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/jco.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391\u2013402. https:\/\/doi.org\/10.1200\/jco.21.00662.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04583-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:01:37Z","timestamp":1791104497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":29,"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04583-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained ethical clearance from the institutional review board (No. bc20261731) and was conducted following the principles outlined in the Declaration of Helsinki (2013 revision).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Tianjin Medical University Cancer Hospital (No. bc20261731). The requirement for informed consent was waived by the Institutional Review Board because of the retrospective nature of the study and the use of de-identified clinical data.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}